

Late 2021	<p><b>September 22:</b> FDA expands Pfizer-BioNTech EUA to authorize booster doses for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19.</p>
	<p><b>November 2:</b> CDC ACIP recommends Pfizer-BioNTech pediatric COVID-19 vaccine for children 5 to 11 years.</p>
	<p><b>November 19:</b> FDA amended the EUA for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age.</p>
	<p><b>November 26:</b> WHO classifies a new variant, Omicron, as a variant of concern.</p>
Early 2022	<p><b>January 5:</b> CDC endorses ACIP recommendation to expand eligibility of booster doses to those 12-15 years old.</p>
	<p><b>January 22:</b> FDA licenses COVID-19 vaccine Spikevax (Moderna) for individuals 18 years and older.</p>
	<p><b>March 17:</b> A Johns Hopkins Bloomberg School of Public Health study found that harassment of public health officials was widespread during the initial phase of the pandemic, March 2020-January 2021.</p>
	<p><b>April 20:</b> CDC ACIP recommends second booster doses for adults 50 years and older.</p>
Mid 2022	<p><b>June 14:</b> FDA issues EUA for a two-dose Moderna COVID-19 vaccines series for children ages 6-11 years and ages 12-17.</p>
	<p><b>June 15:</b> FDA issues EUA for both the Moderna COVID-19 vaccine 2-dose primary series for children 6 months - 5 years and the Pfizer 3-dose series for children 6 months - 4 years.</p>
	<p><b>June 18:</b> CDC ACIP recommends the Moderna and Pfizer COVID-19 vaccines for young children 6mos to 5/6 years of age.</p>
	<p><b>June 23:</b> CDC ACIP recommends a two-dose Moderna COVID-19 vaccines series for children ages 6-11 years, under the EUA issued by FDA.</p>
	<p><b>July 13:</b> FDA issues EUA for Novavax COVID-19 vaccine.</p>
Late 2022	<p><b>September 1 or 2:</b> ACIP will likely meet to discuss Moderna and Pfizer bivalent COVID-19 booster for adults.</p>